ALK6 (BMPR1B) siRNA Set I(B05-911)
FOR BULK ORDER REQUESTS PLEASE CONTACT US
Description :ALK6 (BMPR1B) is a pool of three individual synthetic siRNA duplexes designed to knock-down human ALK6 (BMPR1B) mRNA expression. Each siRNA is 19-25 bases in length.
Specificity :ALK6 (BMPR1B) siRNAs are designed to specifically knock-down human ALK6 (BMPR1B) expression.
Formulation :The siRNAs are supplied as a lyophilized powder and shipped at room temperature.
Reconstitution Protocol :Briefly centrifuge the tubes (maximum RCF 4,000g) to collect lyophilized siRNA at the bottom of the tube. Resuspend the siRNA in 50 ul of DEPC-treated water (supplied by researcher), which results in a 1x stock solution (10 uM). Gently pipet the solution 3-5 times to mix and avoid the introduction of bubbles. Optional: aliquot 1x stock solutions for storage.
Storage and Stability :The lyophilized powder is stable for at least 4 weeks at room temperature. It is recommended that the lyophilized and resuspended siRNAs are stored at or below -20oC. After resuspension, siRNA stock solutions ≥2 uM can undergo up to 50 freeze-thaw cycles without significant degradation. For long-term storage, it is recommended that the siRNA is stored at -70oC. For most favorable performance, avoid repeated Handling and multiple freeze/thaw cycles.
Format :Lyophilized powder
Gene Aliases :ALK-6; ALK6; CDw293
Scientific Background :ALK6 (also known as BMPR1B) is a member of the transmembrane serine/threonine kinase that is the member of the bone morphogenetic protein (BMP) receptor, which is closely related to the activin receptors, ACVR1 and ACVR2. ALK6 is mainly involved in the endochondral bone formation and embryogenesis. ALK6 expressed in normal and cancerous prostate tissues and used in the endocrine therapy that given to the prostate cancer patients (1). ALK6 receptor trafficking also play a significant role in FOP pathogenesis and used in human T-cell differentiation (2).
1. Ide, H. et.al: Cloning of human bone morphogenetic protein type 1B receptor (BMPR-1B) and its expression in prostate cancer in comparison with other BMPRs. Oncogene 14: 1377-1382, 1997.
2. Cejalvo, T. et.al: Bone morphogenetic protein-2/4 signalling pathway components are expressed in the human thymus and inhibit early T-cell development. Immunology 121: 94-104, 2007.
Product Sheets (By Lot #) :
Research Areas :AKT/PKB Pathway, Angiogenesis, Cancer, Cardiovascular Disease, JAK/STAT Pathway, Ser/Thr Kinases, Cancer, Neurobiology, Cardiovascular Disease, AKT/PKB Pathway, JAK/STAT Pathway, Angiogenesis, Ser/Thr Kinases